Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary)
- Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OCEANII
- Sponsors Pierre Fabre
Most Recent Events
- 21 Oct 2024 New source identified and integrated China Drug Trials (CTR20212961).
- 25 Oct 2023 Planned End Date changed from 1 Mar 2025 to 1 May 2025.
- 25 Oct 2023 Planned primary completion date changed from 1 Mar 2025 to 1 May 2025.